Browsing tag:

Januvia


Alogliptin is a current newsmaker in the pharmaceutical industry. On January 25, 2013 Takeda announced that Alogliptin, CAS# 850649-62-6, was approved alongside Metformin HCl, CAS# 1115-70-4, in the novel type 2 diabetes medication Kazano. As an efficacious and highly selective DPP-4 inhibitor, Alogliptin, when combined in this single dose tablet with metformin HCI effectively aids[…]

Read More

Cases of Diabetes, particularly type 2 Diabetes have skyrocketed worldwide and in the United States. According to the National Diabetes Information Clearinghouse Diabetes affects 25.8 million people of all ages, or roughly 8.3 percent of the U.S. population. The majority of these cases in the United States, upwards of 90 percent, are of the type[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service